Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease.

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease. J Gastroenterol Hepatol. 2019 Apr 24;: Authors: Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K Abstract BACKGROUND AND AIM: Oral 5-aminosalicylic acid (5-ASA) is recommended for the therapy of mild to moderate intestinal Behçet’s disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5-ASA…

Read More

Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab.

Related Articles Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab. Clin Gastroenterol Hepatol. 2019 May;17(6):1213-1214 Authors: Fragaki M, Demetriou G, Koutroubakis IE PMID: 31003696 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31003696?dopt=Abstract

Read More

Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.

Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol. 2019 Apr 07;25(13):1603-1617 Authors: Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A Abstract BACKGROUND: Acute severe ulcerative colitis unresponsive to systemic steroid treatment is a life-threatening medical condition requiring hospitalization and often colectomy. Despite the increasing choice of medical therapy options for ulcerative colitis, the condition remains a great challenge in the field of inflammatory bowel diseases (IBD). The performance of the calcineurin inhibitor tacrolimus in this clinical setting is insufficiently…

Read More

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.

Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2019 Apr 13;: Authors: Wu B, Tong J, Ran Z Abstract Inflammatory bowel diseases are known for a chronic inflammatory process of the gastrointestinal tract and include Crohn’s disease and ulcerative colitis (UC). Patients who are dependent on or resistant to corticosteroids account for about 20% of severe UC patients. Tacrolimus is a calcineurin inhibitor that has recently been used in the treatment of steroid-refractory ulcerative colitis. Tacrolimus has been demonstrated to have remarkable therapeutic efficacy in UC patients,…

Read More

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.

Related Articles Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Apr 12;: Authors: Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert…

Read More

Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial.

Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis. 2019 Apr 05;: Authors: Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D, ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa PMID: 30951596 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30951596?dopt=Abstract

Read More

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study.

Related Articles Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019 Mar 28;: Authors: Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH Abstract BACKGROUND: The infliximab biosimilar CT-P13 was approved for use in Crohn’s disease after clinical comparison with originator infliximab…

Read More

Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.

Related Articles Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflamm Bowel Dis. 2019 Apr 01;: Authors: Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC, Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Abstract BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab…

Read More
<< Go Back